NNovartis Read More Novartis confirms more reported tumor cases in Zolgensma patients as SMA groups seek details2026-11-22 Novartis has confirmed a number of new cases of tumors that developed in children treated with its gene…
RRoche Read More Roche, Asahi Kasei, Verastem—Fierce Pharma Asia2026-11-22 Roche extended its China shopping spree with a $1 billion-plus obesity deal. Asahi Kasei’s Hovilpri became the first…
RRoche Read More Sales of Roche’s juggernaut Vabysmo rout the analyst consensus2026-11-22 It’s been eight months since Regeneron secured approval for a high-dose version of its powerhouse macular degeneration treatment Eylea…
NNovartis Read More FDA probes Novartis’ Zolgensma gene therapy over cancer risks2026-11-22 The FDA has launched a safety investigation into Novartis’ gene therapy Zolgensma following reports of tumors in patients,…
NNovartis Read More Novartis buffers price erosion with Cosentyx’s 11th FDA nod2026-11-22 Novartis is eking out the life of its aging immunology med, Cosentyx, with another label expansion. The anti-IL-17…
RRoche Read More Roche pauses future Germany investments2026-11-22 Amid tensions over government healthcare cost-cutting policies, Roche has slammed the brakes on new investments in Germany, joining…
NNovartis Read More Novartis stares down $16.7B post-2030 patent cliff2026-11-22 Novartis is gearing up to defend its growth trajectory against a steep wave of patent expirations in the…
RRoche Read More Roche’s Gazyva wins first FDA nod for membranous nephropathy2026-11-22 As Roche’s Gazyva comes under pressure in blood cancer, the anti-CD20 antibody keeps expanding its reach in autoimmune…
RRoche Read More Roche’s next major breast cancer drug, Wilserdly, wins FDA nod2026-11-22 No breast cancer asset in Roche’s pipeline carries a higher valuation than giredestrant. In fact, the Swiss drugmaker’s…
RRoche Read More Vabysmo shows signs of recovery as Roche gears up for busy 20272026-11-22 After disappointing Wall Street for most of 2026, Roche’s eye disease drug Vabysmo met analysts’ expectations for the…
RRoche Read More Roche-Hanmi, Akeso, a congressman’s concerns—Fierce Pharma Asia2026-11-22 With a potential $2.5 billion deal with Hanmi, Roche is taking a less-trodden path in obesity. Akeso’s CEO…
NNovartis Read More Novartis Remains on a Growth Trajectory Despite Expiring Patents2026-11-19 Pharmaceuticals Novartis Remains on a Growth Trajectory Despite Expiring Patents (File photo) Keystone At its Investor Day, Novartis…